Drugs / Budiglimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04807972 | May 2021 → Mar 2024 | malignant pancreatic neoplasm | AbbVie | Terminated | No outcome recorded Stop: Business |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Budiglimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04807972 ↗ |